Τίτλος:
The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Renal cell carcinoma (RCC) is the most common neoplasm of the kidney. Increasing evidence suggests that microRNAs are dysregulated in RCC and are important factors in RCC pathogenesis. miR-21 is a known oncogene with tumor-promoting effects in many types of cancer. In this study, we analyzed miR-21 in 121 cases of healthy kidney and different RCC subtypes, including clear cell (ccRCC), papillary (pRCC), chromophobe (chRCC), and oncocytoma. Total RNA was extracted, and the expression of miR-21 was measured with real-time quantitative RT-PCR using miR-21-specific probes. The expression of miR-21 was significantly up-regulated in RCC compared with healthy kidney. There was a significant difference in the expression levels between RCC subtypes, with the highest levels of expression in ccRCC and pRCC subtypes. miR-21 expression distinguished ccRCC and pRCC from chRCC and oncocytoma with 90% specificity (95% CI, 63.9% to 98.1%) and 83% sensitivity (95% CI, 53.5% to 97.6%). Significantly higher miR-21 levels were associated with higher stage and grade. Patients who were miR-21 positive had statistically significant shorter disease-free and overall survival rates. Thus, miR-21 is up-regulated in RCC, and its expression levels can be used as a diagnostic marker to distinguish ccRCC and pRCC from chRCC and oncocytoma. Moreover, it has potential as a prognostic marker in RCC, although it is not independent of tumor stage and grade. Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.
Συγγραφείς:
Faragalla, H.
Youssef, Y.M.
Scorilas, A.
Khalil, B.
White, N.M.A.
Mejia-Guerrero, S.
Khella, H.
Jewett, M.A.S.
Evans, A.
Lichner, Z.
Bjarnason, G.
Sugar, L.
Attalah, M.I.
Yousef, G.M.
Περιοδικό:
The Journal of Molecular Diagnostics
Λέξεις-κλειδιά:
bone morphogenetic protein; epidermal growth factor receptor; granulocyte macrophage colony stimulating factor; guanosine triphosphatase; interleukin 3; interleukin 5; interleukin 6; microRNA 21; mitogen activated protein kinase; nerve growth factor; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; platelet derived growth factor; RNA polymerase II; semaphorin; T lymphocyte receptor; toll like receptor; transforming growth factor beta; tuberin; very late activation antigen 2; von Hippel Lindau protein, adult; aged; article; bioinformatics; cancer diagnosis; cancer grading; cancer prognosis; cancer staging; cancer survival; carcinogenicity; chromophobe adenoma; clear cell carcinoma; controlled study; diagnostic value; disease free survival; disease severity; female; human; human tissue; kidney carcinoma; major clinical study; male; oncocytoma; overall survival; papillary carcinoma; protein expression; real time polymerase chain reaction; receiver operating characteristic; reverse transcription polymerase chain reaction; RNA extraction; sensitivity and specificity; signal transduction; upregulation, Carcinoma, Renal Cell; Computational Biology; Humans; Kidney Neoplasms; MicroRNAs; Reverse Transcriptase Polymerase Chain Reaction; Tumor Markers, Biological
DOI:
10.1016/j.jmoldx.2012.02.003
